Understanding Hearing Loss After Tepezza: Prognosis and Management
From General Health to Targeted Therapy Risks
For decades, the general health and science information landscape has emphasized broad wellness principles and community-based care. Initiatives such as the Unity Health Continuity Clinic, which enhances primary care availability, and the annual Day of Caring medical mission reflect a longstanding commitment to accessible, preventive health services. Similarly, specialized programs like Clearview’s focus on memory disorders and senior behavioral medicine highlight the importance of addressing age-related changes in cognition and emotion through comprehensive therapy. Within this legacy of holistic health promotion, a more specific concern has emerged: the potential for therapeutic interventions to introduce unintended risks. As medical treatments advance, the boundary between general health maintenance and targeted therapy becomes increasingly relevant. This is particularly true for individuals exposed to biologic agents in clinical settings, where the benefits of treatment must be weighed against possible adverse effects. One such area of growing attention involves hearing loss following exposure to tepezza. While the broader health context traditionally emphasizes prevention and management of age-related hearing decline, the occupational and clinical exposure to this medication introduces a distinct risk profile. Understanding the prognosis for recovery and the strategies for managing hearing loss after tepezza requires a focused transition from general health principles to the specific challenges posed by therapeutic exposure.
Clinical Presentation and Diagnosis of Hearing Loss
Hearing loss related to Tepezza typically presents as sensorineural hearing loss, which may be unilateral or bilateral. Patients often report a subjective decrease in hearing acuity, tinnitus, or a sensation of ear fullness. The time to onset of symptoms can vary, with reports ranging from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is confirmed through audiometric testing, which may reveal decreased hearing thresholds, particularly in higher frequencies. Clinicians should maintain a high index of suspicion for hearing loss in patients receiving Tepezza, especially if they report auditory symptoms.
Tepezza Pharmacology and Reported Adverse Effects
Tepezza is an insulin-like growth factor-1 receptor (IGF-1R) antagonist. Its mechanism in thyroid eye disease involves blocking IGF-1R on orbital fibroblasts, reducing inflammation and tissue remodeling. However, IGF-1R is expressed in various tissues, including the inner ear, where it plays a role in maintaining cochlear function. The adverse effect profile of Tepezza includes hearing loss, which has been documented in clinical trials and post-marketing reports. The exact incidence is not fully characterized, but the association is considered established. In placebo-controlled studies of similar drugs, the percentages of patients with these symptoms were similar in the drug and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), though this does not directly apply to Tepezza.
Mechanistic Pathways Linking Tepezza to Hearing Loss
The proposed mechanism for Tepezza-induced hearing loss involves disruption of IGF-1R signaling in the cochlea. IGF-1 is essential for the survival and function of hair cells and spiral ganglion neurons. By blocking IGF-1R, Tepezza may impair cellular repair mechanisms and increase susceptibility to damage from noise or other stressors. Additionally, GLP-1 receptor signaling is involved in sinopulmonary inflammatory cascades and recent evidence suggests clinical implications for chronic sinusitis and olfactory disorders (https://pubmed.ncbi.nlm.nih.gov/42126155/). While this evidence pertains to GLP-1 receptors, it highlights the broader role of growth factor signaling in sensory function. Muscle atrophy with weight loss may contribute to a gaunt, aged appearance leading patients to seek facial rejuvenation, or to a patulous eustachian tube and changes in conductive hearing (https://pubmed.ncbi.nlm.nih.gov/42126155/). This suggests that indirect effects on eustachian tube function could also contribute to hearing changes.
Current prescribing information for Tepezza includes warnings about hearing loss, but the adequacy of these warnings is a concern. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that patients may not associate symptoms with the medication if onset is delayed. Physicians should be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue FOSAMAX and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While this warning is for bisphosphonates, it underscores the importance of clear patient instructions for any drug with ototoxic potential. For Tepezza, explicit guidance on hearing loss monitoring and reporting is necessary.
Timeline Between Exposure and Documented Harm
The timeline for hearing loss onset is variable. Some patients develop symptoms within days, while others may not experience hearing changes for months. This variability complicates risk assessment and underscores the need for baseline and periodic audiometry during treatment. Post-marketing surveillance data are critical to better characterize this timeline and identify risk factors.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the prognosis for hearing loss after Tepezza treatment?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.